Lilly Ventures

Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.

Lilly Ventures, established in 2001 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Biotechnology, Life Science, Medical, Financial Services, Venture Capital, Advice, Finance, Payments, Health Care, Therapeutics. The organization boasts a portfolio of 71 investments, with an average round size of $29.1M and 27 successful exits. Their recent investments include Hydra Biosciences, Polaris Partners, Advanced Technology Ventures, Biogen, MedImmune Ventures. The highest investment round they participated in was $207.9B. Among their most notable exits are Hydra Biosciences and Polaris Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.